EyePoint Pharmaceuticals Inc. logo

EyePoint Pharmaceuticals Inc.

EYPT | NASDAQ
Chart Builder DCF Calculator
$4.02
+$0.17 (+4.42%)
At close: Sep 21, 2026, 4:00 PM ET
$3.98
-$0.04 (-1.00%)
Pre-market: Sep 22, 2026, 6:32 AM ET

Market Data

Market Cap
$322.79M
Enterprise Value
$178.94M
Beta
1.64
Average Volume
2.6M
Shares Outstanding (Diluted)
86.54M
Shares Change YoY
23.76%
Institutional Ownership
N/A
Exchange
NASDAQ
ISIN
US30233G2093

Price Performance

Price Change 1M
-22.2%
Price Change 3M
-72.0%
Price Change 6M
-69.2%
Price Change YTD
-77.0%
Price Change 1Y
-69.9%
Price Change 3Y
-52.4%
Price Change 5Y
-65.7%
1M CAGR (ann.)
-70.0%
1Y CAGR (ann.)
-71.8%
5Y CAGR (ann.)
-17.8%
All-Time CAGR
-14.6%

Valuation

PE Ratio
-1.07
Forward PE
N/A
PEG Ratio
0.03
Forward PEG
0.04
PS Ratio
120.85
Forward PS
18.80
PB Ratio
2.03
P/FCF Ratio
-0.96
P/Adj. FCF Ratio
-0.84
P/OCF Ratio
-1.30
EV/Sales
64.16
EV/EBIT
-0.60
EV/EBITDA
-0.61
EV/FCF
-0.51
Earnings Yield
-93.0%
FCF Yield
-104.7%
Adj. FCF Yield
-118.6%

Financial Health

Net Cash
$180.47M
Total Debt
$22.37M
Cash & Short-Term Investments
$180.47M
Total Assets
$228.19M
Current Ratio
4.50
Quick Ratio
4.46
Debt / Equity Ratio
0.13
Debt / EBITDA
-0.08
Debt / FCF
-0.06
OCF / Debt
-15.55
Interest Coverage
0.00
Altman Z-Score
-8.26
Piotroski F-Score
1

Margins & Profitability

Gross Profit Margin
41.8%
Operating Profit Margin
-11365.2%
EBITDA Margin
-10556.1%
Net Profit Margin
-10994.7%
FCF Margin
-12650.6%
Adj. FCF Margin
-14330.4%
SBC / Revenue
1262.6%
SBC Impact (per share)
-13.3%

Returns

Return on Assets
-134.4%
Return on Equity
-135.8%
Return on Invested Capital
-167.8%
Return on Capital Employed
-170.2%
Return on Tangible Assets
-134.4%

Historical Growth (CAGR)

Revenue CAGR 3Y
-57.9%
Revenue CAGR 5Y
-41.0%
Revenue CAGR 10Y
5.6%
EPS CAGR 3Y
-35.6%
EPS CAGR 5Y
-7.8%
EPS CAGR 10Y
14.3%
FCF CAGR 3Y
-60.5%
FCF CAGR 5Y
-56.4%
FCF CAGR 10Y
-30.2%

Analyst Forecasts

Analyst Rating
Buy
Analyst Count
20
EPS Growth Next 3Y
34.3%
Revenue Growth Next 3Y
439.3%
Earnings Date
Nov 3, 2026
EPS Estimate (next Q)
-$0.91
EPS Growth Est (next Q)
6.5%
Revenue Est (next Q)
$231.15K
Revenue Growth Est (next Q)
-76.1%

Fair Value Estimates

Graham Number
N/A
Graham Upside
N/A
Lynch Fair Value
N/A
Lynch Upside
N/A
Price Target
$18.29
Price Target Upside
355.0%

Cash Flow

Operating Cash Flow
$-347.85M
Free Cash Flow
$-352.83M
Adj. Free Cash Flow
$-399.68M
FCF Per Share
-$3.13
OCF Per Share
-$3.09
OCF/S Ratio
-9584.0%

Income Statement

Revenue
$2.79M
Gross Profit
$1.17M
Operating Income
$-316.98M
EBITDA
$-294.41M
Net Income
$-306.64M
EPS (Diluted)
-$3.74
Revenue / Employee
$13.03K
Profit / Employee
$-1.43M
Employees
214

© 2026 bestshares.com. All rights reserved.